MM-associated AL Amyloidosis_Shaji Kumar, MD

Multiple Myeloma /

Multiple Myeloma 119 videos

of 11

119 videos

Multiple Myeloma

MM-associated AL Amyloidosis_Shaji Kumar, MD

53:27
How to Integrate Novel Approaches in the Treatment of Relapsed/Refractory Myeloma_Suzanne Lentzch, MD, PhD; #hemeupdates2022

15:29
New Data in Upfront Management of Multiple Myeloma_Ruben Niesvizky, MD; #hemeupdates2022

12:34
New data in upfront management of multiple myeloma_Sagar Lonial, MD; #BeyondTheCongress

14:31
What are the latest approaches for using CAR T-cell therapy in multiple myeloma?_Nina Shah, MD; #BeyondTheCongress

15:16
Virtual Challenging Case Clinic: Multiple Myeloma - Updates from ASH_Krina Patel, MD, MSc

55:01
Round 3: What is the Optimal Class of Agents for Triple Class Refractory MM?_Sagar Lonial, MD, FACP and Saad Usmani, MD, MBA, FACP

24:44
Q&A: Experts Debate: Treatment Decisions in Relapsed Refractory Multiple Myeloma_Sagar Lonial, MD, FACP_Jonathan Kaufman, MD_Krina Patel, MD, MSc_Saad Usmani, MD, MBA, FACP

28:11
Round 4: What is the Optimal Immunotherapy for Targeting BCMA?_Krina Patel, MD, MSc and Jonathan Kaufman, MD

27:57
Round 1: What is the Optimal Partner for CD38 Therapy in First Relapse_Jonathan Kaufman, MD and Saad Usmani, MD, MBA, FACP

29:23
Round 2: Is MRD Assessment Useful for Treatment Decisions?_Krina Patel, MD, MSc and Sagar Lonial, MD, FACP

27:57
Next Page

of 11

ABOUT

Bio Ascend is an independent medical education company committed to supporting healthcare providers in their efforts to translate innovative science into clinical practice.

The Bio Ascend team has deep oncology and hematology expertise with a proven ability to distill complex scientific ideas into their essential components, as well as extensive experience in planning, executing, and assessing meaningful education for clinicians.

CONNECT

support@bioascend.com

(888) 476-9129

980 North Michigan Avenue, Suite 1400, Chicago, IL 60611

Terms and Conditions | Privacy Policy

MM-associated AL Amyloidosis_Shaji Kumar, MD

How to Integrate Novel Approaches in the Treatment of Relapsed/Refractory Myeloma_Suzanne Lentzch, MD, PhD; #hemeupdates2022

New Data in Upfront Management of Multiple Myeloma_Ruben Niesvizky, MD; #hemeupdates2022

New data in upfront management of multiple myeloma_Sagar Lonial, MD; #BeyondTheCongress

What are the latest approaches for using CAR T-cell therapy in multiple myeloma?_Nina Shah, MD; #BeyondTheCongress

Virtual Challenging Case Clinic: Multiple Myeloma - Updates from ASH_Krina Patel, MD, MSc

Round 3: What is the Optimal Class of Agents for Triple Class Refractory MM?_Sagar Lonial, MD, FACP and Saad Usmani, MD, MBA, FACP

Q&A: Experts Debate: Treatment Decisions in Relapsed Refractory Multiple Myeloma_Sagar Lonial, MD, FACP_Jonathan Kaufman, MD_Krina Patel, MD, MSc_Saad Usmani, MD, MBA, FACP

Round 4: What is the Optimal Immunotherapy for Targeting BCMA?_Krina Patel, MD, MSc and Jonathan Kaufman, MD

Round 1: What is the Optimal Partner for CD38 Therapy in First Relapse_Jonathan Kaufman, MD and Saad Usmani, MD, MBA, FACP

Round 2: Is MRD Assessment Useful for Treatment Decisions?_Krina Patel, MD, MSc and Sagar Lonial, MD, FACP

Share this video

Embed